Drug Profile
Research programme: Alzheimer's disease gene therapy - Amarantus Bioscience Holdings/University of Leipzig
Alternative Names: P16 gene therapy - Amarantus Bioscience Holdings/University of LeipzigLatest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator University of Leipzig
- Developer Amarantus Bioscience Holdings; University of Leipzig
- Class Gene therapies
- Mechanism of Action Cell cycle modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Alzheimer's-disease in Germany
- 01 Aug 2014 Amarantus Bioscience Holdings acquires an exclusive option to in-license the intellectual property covering Alzheimer's disease gene therapy
- 01 Aug 2014 Early research in Alzheimer's disease in Germany (unspecified route)